Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder

Liver Transplantation and Surgery

Volumn 2, Issue 5, 1996, Pages 375-382

  Badley, A D ^a   Portela, D F ^a   Patel, R ^a   Kyle, R A ^a   Habermann, T M ^a   Strickler, J G ^a   Ilstrup, D M ^a   Wiesner, R H ^a   De Groen, P ^a   Walker, R C ^a   Paya, C V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; M PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; VIRUS INFECTION; VIRUS PATHOGENESIS;

EID: 0029786292     PISSN: 10743022     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500020508     Document Type: Article

References (40)

1. 1 Randhawa PS, Markin RS, Starzl TE, Demetris AJ. Epstein‐Barr virus associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition as routine allograft priopsy. Am J Surg Pathol 1990 ; 14: 538–547.
2. 2 Randhawa PS, Jaffe R, Demetris AJ, Nalesnik M, Starzl TE, Chen YY, et al. Expression of Epstein‐Barr virusencoded small RNA (by the EBER‐1 gene) in liver specimens from transplant recipients with post‐transplantation lymphoproliferative disease. N Engl J Med 1992 ; 327: 1710–1714.
3. 3 Straus SE, Cohen J, Tosato G, Meier J. Epstein‐Barr virus infection: Biology, pathogenesis, and management. Ann Intern Med 1993 ; 118: 45–58.
4. 4 Brown NA, Miller G. Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein‐Barr virus. J Immunol 1982 ; 28: 24–29.
5. 5 Rubin RH. Infection in organ transplant recipients. In: Rubin RH, Young LS. Clinical approach to infection in the compromised host. New York: Plenum, 1994.
6. 6 Swinnen LJ, Costanzo‐Nordin MR, Fischer SG, Øullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990 ; 323: 1723–1728.
7. 7 Preiksaitis JK, Diaz‐Mitoma F, Mirzayans F, Roberts S, Tyrrell DL. Quantitative oropharyngeal Epstein‐Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses, and the risk of post‐transplant lymphoproliferative disorder. J Infect Dis 1992 ; 166: 986–994.
8. 8 Rea D, Fourcade C, Leblond V, Rowe M, Joab I, Edelman L, et al. Patterns of Epstein‐Barr virus latent and replicative gene expression in Epstein‐Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994 ; 58: 317–324.
9. 9 Pham H, Lemoine A, Sol O, Azoulay D, Royer P, Samuel D, et al. Monoclonal and oligoclonal gammopathies in liver transplant recipients. Transplantation 1994 ; 58: 253–256.
10. 10 Peest D, Schaper B, Nashan B, Wonigert K, Raude E, Pichlmayn R, et al. High incidence of monoclonal immunoglobulins in patients after liver or heart transplantation. Transplantation 1988 ; 46: 389–394.
11. 11 Deteix P, Chapuis‐Cellier C, Ghaiz Z, LeFrancois N, Brusa M, Touraine JL, et al. Systematic survey of immunoglobulin abnormalities: Frequency and evolution in organ transplant recipients. Transplant Proc 1985 ; 17: 2651–2654.
12. 12 Myara I, Quenum G, Storogenko M, Tenenhaus D, Guillemain R, Moatti N. Monoclonal and oligoclonal gammopathies in heart transplant recipients. Clin Chem 1991 ; 37: 1334–1337.
13. 13 Kyle RA. The monoclonal gammopathies. Clin Chem 1994 ; 40: 2154–2161.
14. 14 Kyle RA. „Benign”︁ monoclonal gammopathy—after 20 to 35 years of follow‐up. Mayo Clin Proc 1993 ; 68: 26–36.
15. 15 Paya CV, Hermans PE, Washington JA, Smith TF, Anhalt JP, Wiesner RH, et al. Incidence, distribution and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989 ; 65: 55–64.
16. 16 Sumaya CV. Epstein‐Barr virus serologic testing: Diagnostic indications and interpretations. Ped Infect Dis 1986 ; 5: 337–342.
17. 17 Portela D, Patel R, Larson‐Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995 ; 171: 1014–1018.
18. 18 Nalesnik MA, Jaffee R, Starzl TE, Demitris AJ, Porter K, Burnham, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A‐prednisone immunosuppression. Am J Pathol 1988 ; 133: 173–192.
19. 19 Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, et al. Correlative morphologic molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995 ; 85: 552–565.
20. 20 Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995 ; 20: 1346–1353.
21. 21 Peto R, Peto J. Asymptomatically efficient rank invariant procedures (with discussion). J R Stat Soc Series B 1972 ; 135: 185–207.
22. 22 Cox DR. Regression in models and life tables (with discussion). J R Stat Soc Series V 1972 ; 34: 187–200.
23. 23 Kelbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980 ; 122–140.
24. 24 Penn I, Brunson ME. Cancers after cyclosporin therapy. Transplantation 1987 ; 43: 32–35.
25. 25 Opelz G, Henderson R. Incidence of non‐Hodgkin lymphoma in kidney and heart transplant recipients. The Lancet 1993 ; 342: 1514–1516.
26. 26 Swinnen LJ, Costanzo‐Nordin MR, Fisher SG, Øullivan EJ, Johnson MR, Heroux AL, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990 ; 323: 1723–1728.
27. 27 Smith JL, Wilkinson AH, Hunsicker J, Tobacman J, Kapelanski DP, Johnson M, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplant Proc 1989 ; 21: 3199–3200.
28. 28 Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein‐Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995 ; 14: 214–221.
29. 29 Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein Barr virus latent membrane protein‐1 (LMP‐1) induces interleukin‐10 production in Burkitt lymphoma lines. Int J Cancer 1994 ; 57: 240–244.
30. 30 Burdin N, Peronne C, Banchereau J, Rousset F. Epstein Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med 1993 ; 177: 295–304.
31. 31 Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor B cooperate to induce anti CD40‐activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992 ; 175: 671–682.
32. 32 Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Halder S, et al. Lymphomagenesis in the SCID‐hu mouse involves abundant production of human interleukin 10. Blood 1995 ; 85: 1063–1074.
33. 33 Sarawar S, Doherty PC. Concurrent production of interleukin 2, interleukin 10, and gamma interferon in the regional lymph nodes of mice with influenza pneumonia. J Virol 1994 ; 68: 3112–3119.
34. 34 Durandy A, Emilie D, Peuchmaur M, Forveille M, Clement C, Wijdenes J, et al. Role of IL6 in promoting growth of human EBV‐induced B‐cell tumors in severe combined immunodeficiency mice. J Immunol 1994 ; 152: 5361–5367.
35. 35 Bende RJ, Jochems GJ, Frame TH, Klein MR, van Eijk RV, van Leir RA, et al. Effects of IL4, IL5, and IL6 on growth and immunoglobulin production of Epstein Barr virus infected human B cells. Cell Immunol 1992 ; 143: 310–323.
36. 36 Devergne O, Peuchmaur M, Humbert M, Navratil E, Leger‐Ravet MB, Crevon MC, et al. In vivo expression of IL1 beta and IL6 genes during viral infections in human. Europ Cytokine Network 1991 ; 2: 183–194.
37. 37 Hambert M, Dalattre RM, Fattal S, Rain B, Cerrina J, Dartevelle P, et al. In situ production of interleukin 6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Transplantation 1993 ; 56: 623–627.
38. 38 Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin 6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993 ; 91: 2806–2814.
39. 39 Randhawa PS, Jaffe R, Demetris AJ, Nalesnik M, Starzl TE, Chen YY, Weiss LM. Expression of Epstein‐Barr virus encoded small RNA (by the EBER‐1 gene) in liver specimens from transplant recipients with posttransplantation lymphoproliferative disease. N Engl J Med 1992 ; 327: 1710–1724.
40. 40 Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein‐Barr virus (EBV)‐infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solidorgan transplant recipients. Blood 1994 ; 84: 972–984.